<DOC>
	<DOCNO>NCT00069758</DOCNO>
	<brief_summary>Summary : As open label study , patient receive SDX-105 30-60 minute intravenous infusion day 1 day 2 . Treatment repeat every 21 day . Treatment continue one year absence disease progression unacceptable toxicity . Patients follow disease progression . Rationale : Drugs use chemotherapy , SDX-105 , use different way stop tumor cell divide stop grow die . Purpose : This study evaluate effectiveness safety non-Hodgkin 's lymphoma patient refractory Rituxan .</brief_summary>
	<brief_title>Safety Activity SDX-105 ( Bendamustine ) Patients With Rituximab Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Documented indolent transform BCell NHL indolent NHL : follicular BCell lymphoma , diffuse small lymphocytic lymphoma , lymphoplasmacytic lymphoma , marginal zone lymphoma Documented refractory disease rituximab therapy , give single agent combination ( defined response , progression within 6 month complete rituximab treatment . ) Age least 18 year Screening Visit ( Site specific requirement may differ ) Previous chemotherapy immunotherapy within 3 week prior enter study ( 6 week nitrosoureas mitomycin ) failure recover adverse event due agent administer previously . Use investigational agent within 28 day study History prior high dose chemotherapy allogeneic stem cell support</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>NHL , indolent NHL , non-Hodgkin 's lymphoma , lymphoma</keyword>
</DOC>